Insellar raises €400K pre-seed to build depression BCI in Berlin — European psychiatric BCI ecosystem grows
Summary
Berlin-based Insellar raised approximately €400K in a pre-seed round in April 2026 to build a functional prototype and generate preclinical proof of concept for its depression-focused BCI and neurostimulation device. Insellar is focused on Germany and Europe first with a clinical problem that is global in scope. The raise adds another European company to the growing psychiatric BCI ecosystem, alongside MintNeuro (UK chips), CorTec (Germany closed-loop BCI), and Motif Neurotech's ARIA-funded work. Germany's established BCI regulatory familiarity from INBRAIN's graphene work and CorTec's first-in-human stroke study makes it a natural base for novel psychiatric BCI development.
Why it matters
Insellar represents the European grassroots of the psychiatric BCI movement — a very early stage company bootstrapping toward a problem that Motif Neurotech is tackling with $30M+ in the US. The €400K pre-seed reflects European angel investing patterns for deep tech, where proof-of-concept funding is smaller but more accessible than US seed rounds. German clinical infrastructure for BCI is rapidly developing.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial